Advanced search
Publication Cover
Expert Review of Vaccines Volume 12, 2013 - Issue 7
Submit an article Journal homepage
1,182
Views
116
CrossRef citations to date
0
Altmetric
Special Focus: Vaccine Adjuvants - Review

An update on safety and immunogenicity of vaccines containing emulsion-based adjuvants

Christopher B Fox IDRI, 1616 Eastlake Ave E., Ste 400, Seattle, WA 98102, USA. [email protected]; IDRI, 1616 Eastlake Ave E., Ste 400, Seattle, WA 98102, USA. [email protected]
&
Jean Haensler Sanofi Pasteur, R&D Department, Campus Mérieux, Marcy l’Etoile 69280, France; Sanofi Pasteur, R&D Department, Campus Mérieux, Marcy l’Etoile 69280, France
Pages 747-758 | Published online: 09 Jan 2014

References

  • Whitmore ER. Lipovaccines, with special reference to public health work. Am. J. Public Health (N. Y). 9(7), 504–507 (1919).
  • Lewis PA, Dodge FW. The sterilization of lipovaccines. J. Exp. Med. 31(2), 169–175 (1920).
  • Freund J, Bonanto MV. The effect of paraffin oil, lanolin-like substances and killed tubercle bacilli on immunization with diphtheric toxoid and bact. Typhosum. J. Immunol. 48, 325–334 (1944).
  • Freund J, Casals J, Hosmer EP. Sensitization and antibody formation after injection of tubercle bacilli and paraffin oil. Proc. Soc. Exp. Biol. Med. 37, 509–513 (1937).
  • Edelman R. Vaccine adjuvants. Rev. Infect. Dis. 2(3), 370–383 (1980).
  • Stewart-Tull DES. Freund’s complete and incomplete adjuvants, preparation, and quality control standards for experimental laboratory animals use. In: Vaccine Adjuvants: Methods and Protocols. Davies G (Ed.). Springer, NY, USA 59–72 (2010).
  • Hilleman MR. Personal historical chronicle of six decades of basic and applied research in virology, immunology, and vaccinology. Immunol. Rev. 170, 7–27 (1999).
  • Allison AC, Byars NE. Syntex adjuvant formulation. Res. Immunol. 143(5), 519–525 (1992).
  • Ott G, Radhakrishnan R, Fang JH, Hora M. The adjuvant MF59: a 10-year perspective. Methods Mol. Med. 42, 211–228 (2000).
  • Fox CB. Squalene emulsions for parenteral vaccine and drug delivery. Molecules 14(9), 3286–3312 (2009).
  • Klucker MF, Dalençon F, Probeck P, Haensler J. AF03, an alternative squalene emulsion-based vaccine adjuvant prepared by a phase inversion temperature method. J. Pharm. Sci. 101(12), 4490–4500 (2012).
  • Fox CB, Huynh C, O’Hara MK, Onu A. Technology transfer of oil-in-water emulsion adjuvant manufacturing for pandemic influenza vaccine production in Romania. Vaccine 31(12), 1633–1640 (2013).
  • European Medicines Agency. CHMP assessment report for Pandemrix. London, UK (2009).
  • Ott G, Barchfeld GL, Chernoff D, Radhakrishnan R, van Hoogevest P, Van Nest G. MF59: design and evaluation of a safe and potent adjuvant for human vaccines. In: Vaccine design: the subunit and adjuvant approach. Powell MF, Newman MJ (Eds). Plenum Press, New York, NY, USA 277–296 (1995).
  • Bachmann MF, Jennings GT. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat. Rev. Immunol. 10(11), 787–796 (2010).
  • Novartis. New Zealand Data Sheet. Fluad, Auckland, NZ, USA (2011).
  • European Medicines Agency. European public assessment report for Pandemrix. London, UK (2012).
  • O’Hagan DT, Ott GS, De Gregorio E, Seubert A. The mechanism of action of MF59 – an innately attractive adjuvant formulation. Vaccine 30(29), 4341–4348 (2012).
  • Morel S, Didierlaurent A, Bourguignon P et al. Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine 29(13), 2461–2473 (2011).
  • Seubert A, Calabro S, Santini L et al. Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88. Proc. Natl Acad. Sci. USA 108(27), 11169–11174 (2011).
  • Ellebedy AH, Lupfer C, Ghoneim HE, DeBeauchamp J, Kanneganti TD, Webby RJ. Inflammasome-independent role of the apoptosis-associated speck-like protein containing CARD (ASC) in the adjuvant effect of MF59. Proc. Natl Acad. Sci. USA 108(7), 2927–2932 (2011).
  • Hui GS, Hashimoto CN. Adjuvant formulations possess differing efficacy in the potentiation of antibody and cell mediated responses to a human malaria vaccine under selective immune genes knockout environment. Int. Immunopharmacol. 8(7), 1012–1022 (2008).
  • Ellebedy AH, Lupfer C, Ghoneim HE, DeBeauchamp J, Kanneganti TD, Webby RJ. Inflammasome-independent role of the apoptosis-associated speck-like protein containing CARD (ASC) in the adjuvant effect of MF59. Proc. Natl Acad. Sci. 110, 4429 (2013).
  • Garçon N, Vaughn DW, Didierlaurent AM. Development and evaluation of AS03, an Adjuvant System containing a-tocopherol and squalene in an oil-in-water emulsion. Expert Rev. Vaccines 11(3), 349–366 (2012).
  • O’Hagan DT, Ott GS, Nest GV, Rappuoli R, Giudice GD. The history of MF59(®) adjuvant: a phoenix that arose from the ashes. Expert Rev. Vaccines 12(1), 13–30 (2013).
  • Walker WT, Faust SN. Monovalent inactivated split-virion AS03-adjuvanted pandemic influenza A (H1N1) vaccine. Expert Rev. Vaccines 9(12), 1385–1398 (2010).
  • Whitaker J, Rouphael N, Mulligan MJ. MF59: an oil-in-water adjuvant. In: Emulsion-Based Vaccine Adjuvants. Fox CB, Carter D, Reed SG (Eds). Future Medicine, London, UK, 7–19 (2012).
  • Cox M. Update on clinical trials evaluation of adjuvanted rHA(H5) vaccines. Presented at: 7th WHO Meeting on Evaluation of Pandemic Influenza Vaccines in Clinical Trials. 17–18 February 2011, Geneva, Switzerland.
  • Foglia G, Sheldon E. Emulsion-adjuvanted clade 2 influenza A/H5N1 vaccine: a randomized, placebo-controlled antigen and adjuvant dose-ranging Phase I clinical trial in healthy adults. Presented at: 12th Annual Conference on Vaccines Research. 7–9 May 2009, Baltimore, MD, USA.
  • Levie K, Leroux-Roels I, Hoppenbrouwers K et al. An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults. J. Infect. Dis. 198(5), 642–649 (2008).
  • Del Giudice G, Fragapane E, Della Cioppa G, Rappuoli R. Aflunov®: a vaccine tailored for pre-pandemic and pandemic approaches against influenza. Expert Opin. Biol. Ther. 13(1), 121–135 (2013).
  • Gasparini R, Amicizia D, Lai PL, Panatto D. Aflunov(®): a prepandemic influenza vaccine. Expert Rev. Vaccines 11(2), 145–157 (2012).
  • Baras B, Bouveret N, Devaster JM et al. A vaccine manufacturer’s approach to address medical needs related to seasonal and pandemic influenza viruses. Influenza Other Respi. Viruses 2(6), 251–260 (2008).
  • Carter NJ, Plosker GL. Prepandemic influenza vaccine H5N1 (split virion, inactivated, adjuvanted) [Prepandrix]: a review of its use as an active immunization against influenza A subtype H5N1 virus. BioDrugs 22(5), 279–292 (2008).
  • Jones T. GSK’s novel split-virus adjuvanted vaccines for the prevention of the H5N1 strain of avian influenza infection. Curr. Opin. Mol. Ther. 11(3), 337–345 (2009).
  • Galli G, Hancock K, Hoschler K et al. Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine. Proc. Natl Acad. Sci. USA 106(19), 7962–7967 (2009).
  • Risi G, Frenette L, Langley JM et al. Immunological priming induced by a two-dose series of H5N1 influenza antigen, administered alone or in combination with two different formulations of AS03 adjuvant in adults: results of a randomised single heterologous booster dose study at 15 months. Vaccine 29(37), 6408–6418 (2011).
  • Stöhr K. Vaccinate before the next pandemic? Nature 465(7295), 161 (2010).
  • Khurana S, Verma N, Yewdell JW et al. MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines. Sci. Transl. Med. 3(85), 85ra48 (2011).
  • O’Hagan DT, Rappuoli R, De Gregorio E, Tsai T, Del Giudice G. MF59 adjuvant: the best insurance against influenza strain diversity. Expert Rev. Vaccines 10(4), 447–462 (2011).
  • Treanor JJ, Campbell JD, Zangwill KM, Rowe T, Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N. Engl. J. Med. 354(13), 1343–1351 (2006).
  • Bresson JL, Perronne C, Launay O et al. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: Phase I randomised trial. Lancet 367(9523), 1657–1664 (2006).
  • Arguedas A, Soley C, Abdelnour A et al.; Costa Rican H1N1 Vaccine Study Group. Assessment of the safety, tolerability and kinetics of the immune response to A/H1N1v vaccine formulations with and without adjuvant in healthy pediatric subjects from 3 through 17 years of age. Hum. Vaccin. 7(1), 58–66 (2011).
  • Block SL, Ruiz-Palacios GM, Guerrero ML, Beygo J, Sales V, Holmes SJ. Dose-range study of MF59-adjuvanted versus nonadjuvanted monovalent A/H1N1 pandemic influenza vaccine in six- to less than thirty-six-month-old children. Pediatr. Infect. Dis. J. 31(7), e92–e98 (2012).
  • Vesikari T, Pepin S, Kusters I, Hoffenbach A, Denis M. Assessment of squalene adjuvanted and non-adjuvanted vaccines against pandemic H1N1 influenza in children 6 months to 17 years of age. Hum. Vaccin. Immunother. 8(9), 1283–1292 (2012).
  • Faenzi E, Zedda L, Bardelli M et al. One dose of an MF59-adjuvanted pandemic A/H1N1 vaccine recruits pre-existing immune memory and induces the rapid rise of neutralizing antibodies. Vaccine 30(27), 4086–4094 (2012).
  • Leroux-Roels I, Roman F, Forgus S et al. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study. Vaccine 28(3), 849–857 (2010).
  • Galli G, Medini D, Borgogni E et al. Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels. Proc. Natl Acad. Sci. USA 106(10), 3877–3882 (2009).
  • Roman F, Clément F, Dewé W et al. Effect on cellular and humoral immune responses of the AS03 adjuvant system in an A/H1N1/2009 influenza virus vaccine administered to adults during two randomized controlled trials. Clin. Vaccine Immunol. 18(5), 835–843 (2011).
  • Ortqvist A, Berggren I, Insulander M, de Jong B, Svenungsson B. Effectiveness of an adjuvanted monovalent vaccine against the 2009 pandemic strain of influenza A(H1N1)v, in Stockholm County, Sweden. Clin. Infect. Dis. 52(10), 1203–1211 (2011).
  • Simpson CR, Ritchie LD, Robertson C, Sheikh A, McMenamin J. Vaccine effectiveness in pandemic influenza – primary care reporting (VIPER): an observational study to assess the effectiveness of the pandemic influenza A (H1N1)v vaccine. Health Technol. Assess. 14(34), 313–346 (2010).
  • Van Buynder PG, Dhaliwal JK, Van Buynder JL et al. Protective effect of single-dose adjuvanted pandemic influenza vaccine in children. Influenza Other Respi. Viruses 4(4), 171–178 (2010).
  • Andrews N, Waight P, Yung CF, Miller E. Age-specific effectiveness of an oil-in-water adjuvanted pandemic (H1N1) 2009 vaccine against confirmed infection in high risk groups in England. J. Infect. Dis. 203(1), 32–39 (2011).
  • Walker WT, Faust SN. AS03 adjuvant. In: Emulsion-Based Vaccine Adjuvants. Fox CB, Carter D, Reed SG (Eds). Future Medicine, London, UK, 21–36 (2012).
  • Siegrist CA, Ambrosioni J, Bel M et al.; H1N1 study group. Responses of solid organ transplant recipients to the AS03-adjuvanted pandemic influenza vaccine. Antivir. Ther. (Lond.) 17(5), 893–903 (2012).
  • Durando P, Icardi G, Ansaldi F. MF59-adjuvanted vaccine: a safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk. Expert Opin. Biol. Ther. 10(4), 639–651 (2010).
  • El Sahly H. MF59™; as a vaccine adjuvant: a review of safety and immunogenicity. Expert Rev. Vaccines 9(10), 1135–1141 (2010).
  • Della Cioppa G, Vesikari T, Sokal E, Lindert K, Nicolay U. Trivalent and quadrivalent MF59(®)-adjuvanted influenza vaccine in young children: a dose- and schedule-finding study. Vaccine 29(47), 8696–8704 (2011).
  • Vesikari T, Groth N, Karvonen A, Borkowski A, Pellegrini M. MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination. Vaccine 27(45), 6291–6295 (2009).
  • Vesikari T, Knuf M, Wutzler P et al. Oil-in-water emulsion adjuvant with influenza vaccine in young children. N. Engl. J. Med. 365(15), 1406–1416 (2011).
  • McElhaney JE, Beran J, Devaster JM et al. S03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial. Lancet Infect. Dis. 13(6), 485–496, 2013.
  • Corey L, Langenberg AG, Ashley R et al. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: two randomized controlled trials. Chiron HSV Vaccine Study Group. JAMA 282(4), 331–340 (1999).
  • Heineman TC, Clements-Mann ML, Poland GA et al. A randomized, controlled study in adults of the immunogenicity of a novel hepatitis B vaccine containing MF59 adjuvant. Vaccine 17(22), 2769–2778 (1999).
  • Frey SE, Houghton M, Coates S et al. Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. Vaccine 28(38), 6367–6373 (2010).
  • Bernstein DI, Schleiss MR, Berencsi K et al. Effect of previous or simultaneous immunization with canarypox expressing cytomegalovirus (CMV) glycoprotein B (gB) on response to subunit gB vaccine plus MF59 in healthy CMV-seronegative adults. J. Infect. Dis. 185(5), 686–690 (2002).
  • Pass RF, Zhang C, Evans A et al. Vaccine prevention of maternal cytomegalovirus infection. N. Engl. J. Med. 360(12), 1191–1199 (2009).
  • McFarland EJ, Borkowsky W, Fenton T et al.; AIDS Clinical Trials Group 230 Collaborators. Human immunodeficiency virus type 1 (HIV-1) gp120-specific antibodies in neonates receiving an HIV-1 recombinant gp120 vaccine. J. Infect. Dis. 184(10), 1331–1335 (2001).
  • Spearman P, Lally MA, Elizaga M et al.; HIV Vaccine Trials Network of NIAID. A trimeric, V2-deleted HIV-1 envelope glycoprotein vaccine elicits potent neutralizing antibodies but limited breadth of neutralization in human volunteers. J. Infect. Dis. 203(8), 1165–1173 (2011).
  • Stoute JA, Slaoui M, Heppner DG et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N. Engl. J. Med. 336(2), 86–91 (1997).
  • Sun P, Schwenk R, White K et al. Protective immunity induced with malaria vaccine, RTS,S, is linked to Plasmodium falciparum circumsporozoite protein-specific CD4+ and CD8+ T cells producing IFN-γ. J. Immunol. 171(12), 6961–6967 (2003).
  • Spring MD, Cummings JF, Ockenhouse CF et al. Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A. PLoS ONE 4(4), e5254 (2009).
  • Thera MA, Doumbo OK, Coulibaly D et al. Safety and immunogenicity of an AMA-1 malaria vaccine in Malian adults: results of a Phase 1 randomized controlled trial. PLoS ONE 3(1), e1465 (2008).
  • Thera MA, Doumbo OK, Coulibaly D et al. Safety and immunogenicity of an AMA1 malaria vaccine in Malian children: results of a Phase 1 randomized controlled trial. PLoS ONE 5(2), e9041 (2010).
  • Cummings JF, Spring MD, Schwenk RJ et al. Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infection. Vaccine 28(31), 5135–5144 (2010).
  • Thera MA, Doumbo OK, Coulibaly D et al. A field trial to assess a blood-stage malaria vaccine. N. Engl. J. Med. 365(11), 1004–1013 (2011).
  • Kester KE, Cummings JF, Ofori-Anyinam O et al.; RTS,S Vaccine Evaluation Group. Randomized, double-blind, Phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J. Infect. Dis. 200(3), 337–346 (2009).
  • Owusu-Agyei S, Ansong D, Asante K et al. Randomized controlled trial of RTS,S/AS02D and RTS,S/AS01E malaria candidate vaccines given according to different schedules in Ghanaian children. PLoS ONE 4(10), e7302 (2009).
  • Regules JA, Cummings JF, Ockenhouse CF. The RTS,S vaccine candidate for malaria. Expert Rev. Vaccines 10(5), 589–599 (2011).
  • Leroux-Roels I, Forgus S, De Boever F et al.; M72 Study Group. Improved CD4(+) T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: a randomized trial. Vaccine 31(17), 2196–2206 (2013).
  • Leroux-Roels I, Koutsoukos M, Clement F et al. Strong and persistent CD4+ T-cell response in healthy adults immunized with a candidate HIV-1 vaccine containing gp120, Nef and Tat antigens formulated in three Adjuvant Systems. Vaccine 28(43), 7016–7024 (2010).
  • Beran J, Hobzova L, Wertzova V et al. Safety and immunogenicity of an investigational adjuvanted hepatitis B vaccine (HB-AS02V) in healthy adults. Hum. Vaccin. 6(7), 578–584 (2010).
  • Surquin M, Tielemans C, Nortier J et al. Anti-HBs antibody persistence following primary vaccination with an investigational AS02(v)-adjuvanted hepatitis B vaccine in patients with renal insufficiency. Hum. Vaccin. 7(9), 913–918 (2011).
  • Fabrizi F, Dixit V, Messa P, Martin P. Hepatitis B virus vaccine in chronic kidney disease: improved immunogenicity by adjuvants? A meta-analysis of randomized trials. Vaccine 30(13), 2295–2300 (2012).
  • Garçon N, Van Mechelen M. Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems. Expert Rev. Vaccines 10(4), 471–486 (2011).
  • Coler RN, Bertholet S, Moutaftsi M et al. Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. PLoS ONE 6(1), e16333 (2011).
  • Lambert SL, Yang CF, Liu Z et al. Molecular and cellular response profiles induced by the TLR4 agonist-based adjuvant Glucopyranosyl Lipid A. PLoS ONE 7(12), e51618 (2012).
  • Stanberry LR, Simon JK, Johnson C et al. Safety and immunogenicity of a novel nanoemulsion mucosal adjuvant W805EC combined with approved seasonal influenza antigens. Vaccine 30(2), 307–316 (2012).
  • GlaxoSmithKline Biologicals. Influenza A (H5N1) virus monovalent vaccine, adjuvanted. Vaccines and Related Biological Products Advisory Committee (VRBPAC) Briefing Document. (2012).
  • Banzhoff A, Haertel S, Praus M. Passive surveillance of adverse events of an MF59-adjuvanted H1N1v vaccine during the pandemic mass vaccinations. Hum. Vaccin. 7(5), 539–548 (2011).
  • Pellegrini M, Nicolay U, Lindert K, Groth N, Della Cioppa G. MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database. Vaccine 27(49), 6959–6965 (2009).
  • Schultze V, D’Agosto V, Wack A, Novicki D, Zorn J, Hennig R. Safety of MF59 adjuvant. Vaccine 26(26), 3209–3222 (2008).
  • Carmona A, Omeñaca F, Tejedor JC et al. Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6–35 months. Vaccine 28(36), 5837–5844 (2010).
  • Waddington CS, Walker WT, Oeser C et al. Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study. BMJ 340, c2649 (2010).
  • Department of Health. Influenza. In: Immunisation Against Infectious Disease – The ‘Green Book’. Salisbury D, Ramsay M, Noakes K (Eds). TSO, Norwich, UK, 185–215 (2011).
  • Esposito S, Pugni L, Daleno C et al. Influenza A/H1N1 MF59-adjuvanted vaccine in preterm and term children aged 6 to 23 months. Pediatrics 127(5), e1161–e1168 (2011).
  • Wijnans L, Weibel D, Sturkenboom M. Adjuvanted versus nonadjuvanted influenza vaccines in young children: comparing results from recent clinical trials. Clin. Invest, 3, 395–408 (2013).
  • Calmy A, Bel M, Nguyen A et al.; H1N1 Study Group. Strong serological responses and HIV RNA increase following AS03-adjuvanted pandemic immunization in HIV-infected patients. HIV Med. 13(4), 207–218 (2012).
  • Launay O, Desaint C, Durier C et al.; ANRS 151 HIFLUVAC Study Group and the French Clinical Vaccinology Network (Réseau National d’Investigation Clinique en Vaccinologie REIVAC). Safety and immunogenicity of a monovalent 2009 influenza A/H1N1v vaccine adjuvanted with AS03A or unadjuvanted in HIV-infected adults: a randomized, controlled trial. J. Infect. Dis. 204(1), 124–134 (2011).
  • Soonawala D, Rimmelzwaan GF, Gelinck LB, Visser LG, Kroon FP. Response to 2009 pandemic influenza A (H1N1) vaccine in HIV-infected patients and the influence of prior seasonal influenza vaccination. PLoS ONE 6(1), e16496 (2011).
  • Fuller JD, Craven DE, Steger KA, Cox N, Heeren TC, Chernoff D. Influenza vaccination of human immunodeficiency virus (HIV)-infected adults: impact on plasma levels of HIV type 1 RNA and determinants of antibody response. Clin. Infect. Dis. 28(3), 541–547 (1999).
  • O’Brien WA, Grovit-Ferbas K, Namazi A et al. Human immunodeficiency virus-type 1 replication can be increased in peripheral blood of seropositive patients after influenza vaccination. Blood 86(3), 1082–1089 (1995).
  • Tasker SA, O’Brien WA, Treanor JJ et al. Effects of influenza vaccination in HIV-infected adults: a double-blind, placebo-controlled trial. Vaccine 16(9-10), 1039–1042 (1998).
  • Meier S, Bel M, L’huillier A et al.; H1N1 Epidemiology Study Group of Geneva. Antibody responses to natural influenza A/H1N1/09 disease or following immunization with adjuvanted vaccines, in immunocompetent and immunocompromised children. Vaccine 29(19), 3548–3557 (2011).
  • Rahier JF, Papay P, Salleron J et al.; European Crohn’s and Colitis Organisation (ECCO). H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapy. Gut 60(4), 456–462 (2011).
  • van Puijenbroek EP, Broos N, van Grootheest K. Monitoring adverse events of the vaccination campaign against influenza A (H1N1) in The Netherlands. Drug Saf. 33(12), 1097–1108 (2010).
  • Heikkinen T, Young J, van Beek E et al. Safety of MF59-adjuvanted A/H1N1 influenza vaccine in pregnancy: a comparative cohort study. Am. J. Obstet. Gynecol. 207(3), 177.e1–177.e8 (2012).
  • Herberts C, Melgert B, van der Laan JW, Faas M. New adjuvanted vaccines in pregnancy: what is known about their safety? Expert Rev. Vaccines 9(12), 1411–1422 (2010).
  • Tsai T, Kyaw MH, Novicki D, Nacci P, Rai S, Clemens R. Exposure to MF59-adjuvanted influenza vaccines during pregnancy – a retrospective analysis. Vaccine 28(7), 1877–1880 (2010).
  • Ludvigsson JF, Zugna D, Cnattingius S, Richiardi L, Ekbom A, Ortqvist A, Persson I, Stephansson O. Influenza H1N1 accination and adverse pregnancy outcome. Eur J Epidemiol. (2013) (Epub ahead of print).
  • De Wals P, Deceuninck G, Toth E et al. Risk of Guillain-Barré syndrome following H1N1 influenza vaccination in Quebec. JAMA 308(2), 175–181 (2012).
  • Dieleman J, Romio S, Johansen K, Weibel D, Bonhoeffer J, Sturkenboom M; VAESCO-GBS Case–Control Study Group. Guillain–Barre syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccine: multinational case–control study in Europe. BMJ 343, d3908 (2011).
  • Salmon DA, Proschan M, Forshee R et al. Lancet 381(9876), 1461–1468, (2013).
  • European Center for Disease Prevention and Control. Narcolepsy in association with pandemic influenza vaccination (a multi-country European epidemiological investigation). Stockholm, Sweden (2012).
  • Nohynek H, Jokinen J, Partinen M et al. AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS ONE 7(3), e33536 (2012).
  • Partinen M, Saarenpää-Heikkilä O, Ilveskoski I et al. Increased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in Finland. PLoS ONE 7(3), e33723 (2012).
  • Heier MS, Gautvik KM, Wannag E et al. Incidence of narcolepsy in Norwegian children and adolescents after vaccination against H1N1 influenza A. Sleep. Med. doi 10.1016/j.sleep.2013.03.020 (2013) (Epub ahead of print).
  • Szakacs A, Darin N, Hallbook T. Increased childhood incidence of narcolepsy in western Sweden after H1N1 influenza vaccination. Neurology 80(14), 1315–1321, (2013).
  • Morris K. Implications of narcolepsy link with swine-influenza vaccine. Lancet Infect Dis 13(5), 396–397, (2013).
  • European Medicines Agency. EMA recommends restricting use of Pandemrix. London, UK (2011).
  • Miller E, Andrews N, Stellitano L et al. Risk of narcolepsy in children and young people receiving AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine: retrospective analysis. BMJ 346, f794 (2013).
  • Tsai TF, Crucitti A, Nacci P et al. Explorations of clinical trials and pharmacovigilance databases of MF59®-adjuvanted influenza vaccines for associated cases of narcolepsy. Scand. J. Infect. Dis. 43(9), 702–706 (2011).
  • Han F, Lin L, Warby SC et al. Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in China. Ann. Neurol. 70(3), 410–417 (2011).
  • FDA. Summary minutes vaccines and related biological products advisory committee. Food and Drug Administration Center for Biologics Evaluation and Review, MD, USA (2012).
  • Seppic. Montanide ISA 51 VG product description. (2012).
  • Seppic. Montanide ISA 720 VG product description. (2012).
  • Rodríguez PC, Rodríguez G, González G, Lage A. Clinical development and perspectives of CIMAvax EGF, Cuban vaccine for non-small-cell lung cancer therapy. MEDICC Rev. 12(1), 17–23 (2010).
  • Graham BS, McElrath MJ, Keefer MC et al.; AIDS Vaccine Evaluation Group. Immunization with cocktail of HIV-derived peptides in montanide ISA-51 is immunogenic, but causes sterile abscesses and unacceptable reactogenicity. PLoS ONE 5(8), e11995 (2010).
  • Wu Y, Ellis RD, Shaffer D et al. Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. PLoS ONE 3(7), e2636 (2008).
  • Sabbatini P, Tsuji T, Ferran L et al. Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC shows rapid induction of integrated immune response in ovarian cancer patients. Clin. Cancer Res. 18(23), 6497–6508 (2012).
  • Atsmon J, Kate-Ilovitz E, Shaikevich D et al. Safety and immunogenicity of multimeric-001 – a novel universal influenza vaccine. J. Clin. Immunol. 32(3), 595–603 (2012).
  • Herrera S, Fernández OL, Vera O et al. Phase I safety and immunogenicity trial of Plasmodium vivax CS derived long synthetic peptides adjuvanted with montanide ISA 720 or montanide ISA 51. Am. J. Trop. Med. Hyg. 84(2 Suppl), 12–20 (2011).
  • Pierce MA, Ellis RD, Martin LB et al. Phase 1 safety and immunogenicity trial of the Plasmodium falciparum blood-stage malaria vaccine AMA1-C1/ISA 720 in Australian adults. Vaccine 28(10), 2236–2242 (2010).
  • McCarthy JS, Marjason J, Elliott S et al. A Phase 1 trial of MSP2-C1, a blood-stage malaria vaccine containing 2 isoforms of MSP2 formulated with Montanide® ISA 720. PLoS ONE 6(9), e24413 (2011).
  • Tefit JN, Serra V. Outlining novel cellular adjuvant products for therapeutic vaccines against cancer. Expert Rev. Vaccines 10(8), 1207–1220 (2011).
  • Widgren K, Magnusson M, Hagstam P, Widerström M, Örtqvist Å, Einemo IM, Follin P, Lindblom A, Mäkitalo S, Wik O, Österlund A, Grünewald M, Uhnoo I, Linde A. Prevailing effectiveness of the 009 influenza A(H1N1)pdm09 vaccine during the 2010/11 season in Sweden. Euro Surveill. 18(15), 20447 (2013).
  • Camin F, Bontempo L, Ziller L, Piangiolino C, Morchio G. Stable isotope ratios of carbon and hydrogen to distinguish olive oil from shark squalene-squalane. Rapid Commun. Mass Spectrom. 24(12), 1810–1816 (2010).
  • Naziri E, Tsimidou MZ. Formulated squalene for food related applications. Recent Pat. Food. Nutr. Agric. 5(2), 83–104 (2013).
  • Brito LA, Chan M, Baudner B et al. An alternative renewable source of squalene for use in emulsion adjuvants. Vaccine 29(37), 6262–6268 (2011).
  • Fox CB, Anderson RC, Dutill TS, Goto Y, Reed SG, Vedvick TS. Monitoring the effects of component structure and source on formulation stability and adjuvant activity of oil-in-water emulsions. Colloids Surf. B. Biointerfaces 65(1), 98–105 (2008).
  • Cockcroft L. Cosmetics giants agree to stop using shark oil. In: The Telegraph. Telegraph Media Group, London, UK (2008).
  • Fox CB, Carter D, Baldwin SL, Reed SG. Innovations in emulsion technology. In: Emulsion-based Vaccine Adjuvants. Fox CB, Carter D, Reed SG (Eds). Future Medicine Ltd, London, 38–51 (2012).
  • Ventura R, Brunner L, Heriyanto B et al. Technology transfer of an oil-in-water vaccine-adjuvant for strengthening pandemic influenza preparedness in Indonesia. Vaccine 31(12), 1641–1645 (2013).
  • Baldwin SL, Fox CB, Pallansch MA, Coler RN, Reed SG, Friede M. Increased potency of an inactivated trivalent polio vaccine with oil-in-water emulsions. Vaccine 29(4), 644–649 (2011).
  • Westdijk J, Koedam P, Barro M et al. Antigen sparing with adjuvanted inactivated polio vaccine based on Sabin strains. Vaccine 31(9), 1298–1304 (2013).
  • Blom AG, Hilgers LA. Sucrose fatty acid sulphate esters as novel vaccine adjuvants: effect of the chemical composition. Vaccine 23(6), 743–754 (2004).
  • Heldens JG, Glansbeek HL, Hilgers LA et al. Feasibility of single-shot H5N1 influenza vaccine in ferrets, macaques and rabbits. Vaccine 28(51), 8125–8131 (2010).
  • Aucouturier J, Dupuis L, Deville S, Ascarateil S, Ganne V. Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines. Expert Rev. Vaccines 1(1), 111–118 (2002).
  • Aucouturier J, Dupuis L, Ganne V. Adjuvants designed for veterinary and human vaccines. Vaccine 19(17-19), 2666–2672 (2001).
  • Hamouda T, Sutcliffe JA, Ciotti S, Baker JR Jr. Intranasal immunization of ferrets with commercial trivalent influenza vaccines formulated in a nanoemulsion-based adjuvant. Clin. Vaccine Immunol. 18(7), 1167–1175 (2011).
  • Iseki K, Matsunaga H, Komatsu N et al. Evaluation of a new oil adjuvant for use in peptide-based cancer vaccination. Cancer Sci. 101(10), 2110–2114 (2010).
  • Yamada A, Noguchi M, Komatsu N et al. Phase I clinical study of a personalized peptide vaccination available for six different human leukocyte antigen (HLA-A2, -A3, -A11, -A24, -A31 and -A33)-positive patients with advanced cancer. Exp. Ther. Med. 2(1), 109–117 (2011).

Patent

  • Hanon EJ, Stephenne J. Novel composition. WO2006100110. GlaxoSmithKline Biologicals (2006).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.